Diant Pharma
DIANT Pharma: Innovating continuous nanoparticle drug and vaccine development since 2019.
Founded
2019DIANT Pharma: Innovating continuous nanoparticle drug and vaccine development since 2019.
Founded in 2019, DIANT Pharma focuses on developing continuous processing technology for nanoparticle drug products and vaccines. Their core mission is to provide pharmaceutical companies with advanced, reliable, and efficient drug encapsulation techniques. Utilizing a proprietary ethanol-injection system, DIANT Pharma forms nanoparticles with controlled particle sizes at high flow rates, ensuring robust and scalable solutions from research and development to full-scale manufacturing. Their market focus includes pharmaceutical companies seeking innovative methods for drug delivery and vaccine production.
Notable figures affiliated with DIANT Pharma include experts in pharmaceutical engineering and continuous manufacturing. The company has attracted significant interest from investors in the biotech sector due to its groundbreaking technology. Key achievements include the successful implementation of their DIANT® Jet technology, which has set new standards in nanoparticle production. Overall, DIANT Pharma has made a substantial impact on the pharmaceutical industry by enhancing the efficiency and effectiveness of drug and vaccine development processes.
Companies similar to Diant Pharma include Nano PharmaSolutions, Ascendia Pharmaceuticals, MAA Laboratories and Dantari.
Diant Pharma was founded in 2019.
Diant Pharma's headquarters is located in Manchester, CT, US.
Diant Pharma's most recent funding round was for $1.4M (USD) in September 2022.
As of Sep 30, 2022, Diant Pharma has disclosed funding of $1.7M (USD). Undisclosed round amounts are excluded.
Diant Pharma has 11 employees as of Feb 5, 2024.
Dantari
dantari.com
